PatientsVille.com LogoPatientsVille.com

Pulmonary Arterial Hypertension | Registry for Pulmonary Hypertension in China

Pulmonary Arterial Hypertension research study

What is the primary objective of this study?

1. To characterize the demographics and clinical course of the patient population diagnosed as having WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension 2. To describe real-world outcome of Chinese patients with WHO group I pulmonary arterial hypertension and WHO group IV pulmonary hypertension due to chronic thromboembolic pulmonary hypertension 3. To evaluate differences in patient outcomes according to classification subgroup 4. To identify clinical predictors of long-term survival 5. To assess the relationship between targeted therapies for pulmonary arterial hypertension and patient outcomes

Who is eligible to participate?

Inclusion Criteria: - Signed patients'consent - Diagnosed by right heart catheterization one month within study enrollment - patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Exclusion Criteria: - Not meeting inclusion criteria

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Pulmonary Arterial Hypertension

Chronic Thromboembolic Pulmonary Hypertension

Death

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Pulmonary hypertension groupPatients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension

Study Status

Recruiting

Start Date: August 2009

Completed Date: December 2020

Phase:

Type: Observational

Design:

Primary Outcome: Survival

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Jian-Guo He, M.D.

Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01417338

Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb;137(2):376-87. doi: 10.1378/chest.09-1140. Epub 2009 Oct 16.

Discuss Hypertension